Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
1.120
+0.160 (16.63%)
At close: Nov 1, 2024, 4:00 PM
1.100
-0.020 (-1.79%)
After-hours: Nov 1, 2024, 6:33 PM EDT
Lyell Immunopharma Employees
Lyell Immunopharma had 224 employees as of December 31, 2023. The number of employees decreased by 50 or -18.25% compared to the previous year.
Employees
224
Change (1Y)
-50
Growth (1Y)
-18.25%
Revenue / Employee
$241
Profits / Employee
-$938,656
Market Cap
286.72M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 224 | -50 | -18.25% |
Dec 31, 2022 | 274 | 55 | 25.11% |
Dec 31, 2021 | 219 | 29 | 15.26% |
Dec 31, 2020 | 190 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Anika Therapeutics | 357 |
Pulmonx | 279 |
Editas Medicine | 265 |
Biodesix | 217 |
Sight Sciences | 214 |
TScan Therapeutics | 154 |
Rigel Pharmaceuticals | 147 |
Inventiva | 123 |
LYEL News
- 1 day ago - Lyell Immunopharma Completes Acquisition of ImmPACT Bio - GlobeNewsWire
- 7 days ago - Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth - Seeking Alpha
- 8 days ago - Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies - GlobeNewsWire
- 4 weeks ago - Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire
- 5 weeks ago - Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day - GlobeNewsWire
- 2 months ago - Lyell Immunopharma Announces Participation in September Investor Conferences - GlobeNewsWire
- 3 months ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024 - GlobeNewsWire
- 4 months ago - Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology - GlobeNewsWire